ATE501720T1 - Immunhemmende pyrazolon-verbindungen - Google Patents

Immunhemmende pyrazolon-verbindungen

Info

Publication number
ATE501720T1
ATE501720T1 AT04798360T AT04798360T ATE501720T1 AT E501720 T1 ATE501720 T1 AT E501720T1 AT 04798360 T AT04798360 T AT 04798360T AT 04798360 T AT04798360 T AT 04798360T AT E501720 T1 ATE501720 T1 AT E501720T1
Authority
AT
Austria
Prior art keywords
inhibitant
immune
pyrazolone compounds
compounds
pyrazolone
Prior art date
Application number
AT04798360T
Other languages
English (en)
Inventor
Ian Matthews
Original Assignee
Medigene Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medigene Ag filed Critical Medigene Ag
Application granted granted Critical
Publication of ATE501720T1 publication Critical patent/ATE501720T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C04CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04BLIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632Organic additives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18One oxygen or sulfur atom
    • C07D231/20One oxygen atom attached in position 3 or 5
    • C07D231/22One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Manufacturing & Machinery (AREA)
  • Ceramic Engineering (AREA)
  • Diabetes (AREA)
  • Materials Engineering (AREA)
  • Structural Engineering (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT04798360T 2003-11-04 2004-11-02 Immunhemmende pyrazolon-verbindungen ATE501720T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0325644.3A GB0325644D0 (en) 2003-11-04 2003-11-04 Immuno ihibitory pyrazolone compounds
PCT/GB2004/004629 WO2005046679A1 (en) 2003-11-04 2004-11-02 Immuno inhibitory pyrazolone compounds

Publications (1)

Publication Number Publication Date
ATE501720T1 true ATE501720T1 (de) 2011-04-15

Family

ID=29725866

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04798360T ATE501720T1 (de) 2003-11-04 2004-11-02 Immunhemmende pyrazolon-verbindungen

Country Status (6)

Country Link
US (2) US7816361B2 (de)
EP (1) EP1703906B1 (de)
AT (1) ATE501720T1 (de)
DE (1) DE602004031878D1 (de)
GB (1) GB0325644D0 (de)
WO (1) WO2005046679A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004081011A1 (en) * 2003-03-14 2004-09-23 Avidex Limited Immunomodulating heterocyclic compounds
US7932253B2 (en) * 2004-08-09 2011-04-26 Medigene Ag Immunomodulating oxopyrrazolocinnolines as CD80 inhibitors
GB0603522D0 (en) * 2006-02-22 2006-04-05 Avidex Ltd Kinase inhibition
CA2816983A1 (en) 2010-11-05 2012-05-10 Senomyx, Inc. Compounds useful as modulators of trpm8
EP2916835A4 (de) * 2012-11-12 2016-07-27 Redwood Bioscience Inc Verbindungen und verfahren zur herstellung eines konjugats
EP2883883A1 (de) 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Therapeutische Ziele und Mittel zur Behandlung von ischämiebedingten Reperfusionsschäden
US10392371B2 (en) 2015-10-01 2019-08-27 Senomyx, Inc. Compounds useful as modulators of TRPM8
EP3886854A4 (de) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrol- und pyrazolverbindungen und verfahren zu deren verwendung
CN117980325A (zh) 2021-05-13 2024-05-03 卡莫特治疗学股份有限公司 G-蛋白偶联受体的调节剂

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB629412A (en) * 1946-12-24 1949-09-20 Geigy Ag J R Manufacture of metallisable monoazo dyestuffs of the pyrazolone series
US3576637A (en) * 1967-04-20 1971-04-27 Konishiroku Photo Ind Lith-type of emulsion containing pyrozolone
US4591589A (en) 1985-01-16 1986-05-27 Roussel Uclaf 2-aryl pyrazolo[4,3-c]cinnolin-3-ones
DE3626221A1 (de) * 1986-08-02 1988-02-04 Agfa Gevaert Ag Farbfotografisches aufzeichnungsmaterial zur herstellung farbiger aufsichtsbilder
US4906644A (en) * 1986-11-20 1990-03-06 Mitsubishi Kasei Corporation Lipid-peroxide formation inhibiting composition and novel compounds useful therefor
DE3903993A1 (de) 1989-02-10 1990-08-16 Basf Ag Diarylsubstituierte heterocyclische verbindungen, ihre herstellung und arzneimittel daraus
AR006520A1 (es) 1996-03-20 1999-09-08 Astra Pharma Prod Derivados de 2-arilpirazolisoquinolina y cinolinona y procedimiento para su preparacion.
GB9713707D0 (en) 1997-06-27 1997-09-03 Merck Sharp & Dohme Therapeutic agents
SE0102404D0 (sv) 2001-07-04 2001-07-04 Active Biotech Ab Novel immunomodulating compounds
RU2328496C2 (ru) 2002-11-22 2008-07-10 Эктив Байотек Аб Пиразолхинолины с иммуномодулирующей активностью
WO2004055014A1 (en) 2002-12-16 2004-07-01 Active Biotech Ab Tetracyclic immunomodulatory compounds
WO2004081011A1 (en) 2003-03-14 2004-09-23 Avidex Limited Immunomodulating heterocyclic compounds

Also Published As

Publication number Publication date
EP1703906B1 (de) 2011-03-16
US20070213345A1 (en) 2007-09-13
WO2005046679A1 (en) 2005-05-26
US8163757B2 (en) 2012-04-24
US20100331342A1 (en) 2010-12-30
GB0325644D0 (en) 2003-12-10
EP1703906A1 (de) 2006-09-27
DE602004031878D1 (de) 2011-04-28
US7816361B2 (en) 2010-10-19

Similar Documents

Publication Publication Date Title
JO2947B1 (en) Compounds corresponding to cyclopamine
TW200503724A (en) Novel pharmaceuticals
EA201000113A1 (ru) Пиразольные соединения
EA200900213A1 (ru) Ингибиторы обратной транскриптазы вич (варианты), фармацевтическая композиция на их основе, способ ингибирования репликации ретровируса с их помощью и названные ингибиторы для изготовления лекарственного средства для ингибирования обратной транскриптазы вич и для лечения или профилактики инфекционного вич
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
TW200738741A (en) Antiviral compounds
TW200738742A (en) Antiviral compounds
TW200626610A (en) Analogs of 17-hydroxywortmannin as PI3K inhibitors
TW200614996A (en) Antiviral compounds
SE0301373D0 (sv) Novel compounds
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
EA200970207A1 (ru) Соединения пиридо[2,3-d]пиримидинона и их применение в качестве pi3 ингибиторов
MXPA05011296A (es) Conjugados de fosfonato inhibidores de la cinasa.
IL163781A0 (en) Purine derivatives as kinase inhibitors
MXPA05009969A (es) Metodo para aislar la forma cristalina i de la 5-azacitidina.
PL1761520T3 (pl) Inhibitory kinazy
EA200801608A1 (ru) Производные бензимидазолонкарбоновой кислоты
GB0127903D0 (en) Improvements relating to organic compounds
EA200970041A1 (ru) Ингибиторы акт (протеинкиназы в)
EA200701328A1 (ru) Замещенные триазольные производные в качестве антагонистов окситоцина
MY143516A (en) Kinase inhibitors
ATE501720T1 (de) Immunhemmende pyrazolon-verbindungen
TW200628153A (en) Novel compounds
DE602004012146D1 (en) Pyrazolopyrimidine
NO20076161L (no) Fremgangsmater for fremstilling av 4-bifenylazetidin-2-oner

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties